EGFR and gastric adenocarcinoma: ERBB2 amplification for anti-ERBB2 inhibitor treatment in breast [12] and gastric adenocarcinomas [13], EGFR amplification for anti-EGFR inhibitors [14], [15], MET amplification for MET tyrosine kinase inhibitors [16], [17], and FGFR2 amplification for FGFR2 phosphorylation inhibitors [18] have been reported as predictive markers.